SLC3A1 — Solute Carrier Family 3 Member 1
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc3a1</th>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">LAT1</td>
<td>SLC7A5</td>
</tr>
<tr>
<td class="label">y+LAT1</td>
<td>SLC7A7</td>
</tr>
<tr>
<td class="label">ASC1</td>
<td>SLC7A10</td>
</tr>
<tr>
<td class="label">xCT</td>
<td>SLC7A11</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">SLC7A9 (b^0,+AT)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">SLC7A13 (KAT-1)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">4F2hc (SLC3A2)</td>
<td>Homology</td>
</tr>
<tr>
<td class="label">Renal luminal AA</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Na^+</td>
<td>Cotransport</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
SLC3A1 (Solute Carrier Family 3 Member 1) encodes the heavy chain subunit rBAT (related to B^0 amino acid transporter), which partners with a light chain to form the heteromeric amino acid transporter (HAT) system. Located on chromosome 2p16.3 (NCBI Gene ID: 10251, OMIM: 104614, Ensembl: ENSG00000166391, UniProt: Q07817), SLC3A1 is primarily expressed in the kidney and intestinal epithelium where it mediates reabsorption of cystine and dibasic amino acids [@palacin2005].
Mutations in SLC3A1 cause type I cystinuria, a disorder characterized by impaired cystine reabsorption in the kidney, leading to cystine stone formation. While SLC3A1 is not classically considered a neurodegeneration gene, amino acid transport across the blood-brain barrier and within neurons is critically important for neuronal function, and transport system dysfunction may contribute to neurodegenerative processes [@chillaron2011].
Gene Structure and Protein Architecture
Gene Organization
The SLC3A1 gene spans approximately 15 kb on chromosome 2p16.3 and consists of 8 exons encoding a 683-amino acid protein. The gene exhibits typical housekeeping gene features with multiple transcription start sites.
Protein Structure
The rBAT protein (79 kDa) is a type II membrane glycoprotein with:
- N-terminal extracellular domain (aa 1-480): Contains multiple N-linked glycosylation sites and the substrate binding interface
- Single transmembrane helix (aa 481-503): Anchors the protein in the plasma membrane
- C-terminal intracellular domain (aa 504-683): Contains trafficking signals and interacts with light chain subunits
rBAT must form a covalent disulfide bond with a light chain (SLC7A9 or SLC7A13) to function as a transporter. This heterodimerization is essential for plasma membrane localization and transport activity [@wagner2001].
The Heteromeric Amino Acid Transporter System
System Organization
Heteromeric amino acid transporters (HATs) consist of:
- Heavy chain (SLC3 family): rBAT (SLC3A1) or 4F2hc (SLC3A2) — provides extracellular domain and disulfide bond formation
- Light chain (SLC7 family): Determines substrate specificity and transport mechanism
Substrate Specificity
The SLC3A1/SLC7A9 heterodimer (system b^0,+) transports:
- Cystine: The oxidized dimer of cysteine
- Dibasic amino acids: Lysine, ornithine, arginine
- Some neutral amino acids: Leucine, isoleucine, phenylalanine
This transporter operates as an exchanger, importing dibasic amino acids in exchange for exporting neutral amino acids and cystine.
Tissue Distribution
SLC3A1 expression is predominantly localized to:
- Proximal renal tubule: Apical membrane of S1-S2 segments
- Small intestine: Apical membrane of enterocytes
- Placenta: Fetal membrane expression
- Low expression in other tissues
SLC3A1 in Kidney Function
Proximal Tubule Reabsorption
SLC3A1-mediated transport is critical for renal amino acid handling:
Apical uptake: The SLC3A1/SLC7A9 heterodimer localizes to the apical membrane of proximal tubular cells, where it reabsorbs filtered amino acids from the glomerular filtrate.
Transcellular pathway: Reabsorbed amino acids exit the cell via basolateral transporters and enter the bloodstream.
Exchange mechanism: The system operates as an exchanger, using the gradient of neutral amino acids to drive cystine/dibasic amino acid uptake.
Pathophysiology of Cystinuria
Type I cystinuria results from SLC3A1 mutations:
Genetic basis:
- Autosomal recessive inheritance
- Over 150 pathogenic mutations identified
- Frameshift, nonsense, and splice-site mutations common
- Missense mutations often affect trafficking or disulfide bonding
Clinical manifestations:
- Recurrent kidney stones (cystine calculi)
- Urinary cystine concentrations 10-20x normal
- Stone formation begins in childhood or adolescence
- Flank pain, hematuria, urinary obstruction
Treatment approaches-:
- High fluid intake to maintain dilute urine
- Alkalinization of urine (increases cystine solubility)
- Cystine-binding medications (tiopronin, penicillamine)
- Dietary sodium restriction
- Stone removal procedures when necessary
Amino Acid Transport and the Brain
Blood-Brain Barrier Transport
While SLC3A1 itself is not highly expressed in the brain, the broader system of amino acid transporters is crucial for brain function:
Essential amino acid transport:
- Large neutral amino acid transporter (LAT1, SLC7A5) at the BBB
- Provides brain access to amino acids needed for neurotransmitter synthesis
- Dysregulation contributes to neurodegenerative processes
Neurotransmitter precursors:
- Tryptophan, tyrosine, phenylalanine uptake for serotonin and catecholamine synthesis
- Impaired transport may affect neurotransmitter levels in disease
Glutamate Transporters
The broader SLC17 family includes vesicular glutamate transporters:
- VGLUT1-3 package glutamate into synaptic vesicles
- Expression in excitatory neurons
- Dysfunction in ALS, Alzheimer's disease
Amino acid transport dysfunction may contribute to excitotoxicity in neurodegeneration [@shental2007].
SLC3A1 in Neurodegenerative Context
While direct evidence linking SLC3A1 to neurodegenerative diseases is limited, the broader context of amino acid transport is highly relevant:
Amino Acid Dysregulation in AD/PD
Alzheimer's disease:
- Altered plasma amino acid levels in AD patients
- Impaired BBB amino acid transport in AD
- CSF/plasma amino acid ratios abnormal
- May affect neurotransmitter precursor availability
Parkinson's disease:
- Altered tryptophan and tyrosine metabolism
- Reduced levodopa transport across BBB in some patients
- Role of amino acid transporters in L-dopa efficacy
Blood-Brain Barrier Function
The BBB expresses multiple amino acid transporters:
Cystine/Glutamate Exchange (System xc-)
The cystine/glutamate antiporter (system xc-, composed of SLC7A11 and SLC3A2):
- Imports cystine for glutathione synthesis
- Exports glutamate
- Important for antioxidant defense
- Implicated in Parkinson's disease (MPTP toxicity)
- Target for neuroprotective strategies
Therapeutic Implications
Amino Acid Transporter Targeting
While SLC3A1 is not a direct therapeutic target for neurodegeneration:
System xc- modulators:
- Sulfasalazine inhibits cystine uptake (used in cancer therapy)
- Ebselen enhances system xc- function
- Potential for neuroprotection in PD
LAT1 modulation:
- LAT1 inhibitors explored for cancer
- Brain delivery of amino acid-based therapeutics
Cystinuria Treatment Implications
For cystinuria patients:
- Long-term stone disease may affect kidney function
- Potential secondary effects on brain through systemic amino acid dysregulation
- Monitoring of systemic amino acid homeostasis
Interaction Network
SLC3A1 interacts with multiple partners:
Clinical Genetics
Cystinuria Genetics
Inheritance: Autosomal recessive
Genotype-phenotype:
- Type I: Homozygous or compound heterozygous SLC3A1 mutations
- Type II: Homozygous SLC7A9 mutations
- Type III: Compound heterozygous SLC3A1/SLC7A9 mutations
Carrier testing: Available for at-risk families
Newborn screening: Not routinely performed (no systemic effects at birth)
Variant Interpretation
- Missense variants: Often affect folding or trafficking
- Nonsense/frameshift: Predicted null alleles
- Splice variants: May cause exon skipping or intron retention
- Variants are evaluated using ACMG guidelines
Research Directions
Structure-Function Studies
- Cryo-EM structures of heterodimeric transporters
- Substrate binding site identification
- Transport mechanism elucidation
Therapeutic Development
- Novel cystine-binding agents
- Gene therapy approaches for cystinuria
- Small molecule correctors of trafficking mutants
Neurodegeneration Connections
- Role of amino acid transport in AD/PD pathogenesis
- System xc- as therapeutic target
- BBB amino acid transporter modulation
References
[Broer & Broer, Amino acid homeostasis and signalling (2017)](https://pubmed.ncbi.nlm.nih.gov/28437836/)
[Kandasamy et al., SLC transporters as therapeutic targets (2020)](https://pubmed.ncbi.nlm.nih.gov/32295719/)
[Hediger et al., The ABCs of solute carriers (2004)](https://pubmed.ncbi.nlm.nih.gov/14624363/)
[Goncalves et al., Glucose transporters in the blood-brain barrier (2013)](https://pubmed.ncbi.nlm.nih.gov/23867246/)
[Shental-Bechor & Ziegler, Neurotransmitter transporters (2007)](https://pubmed.ncbi.nlm.nih.gov/17427990/)
[Verrey et al., Cross-species analysis of PMCAs (2003)](https://pubmed.ncbi.nlm.nih.gov/12521340/)
[Palacin et al., The heteromeric amino acid transporter (2005)](https://pubmed.ncbi.nlm.nih.gov/15917204/)
[Amara et al., Glutamate transporters (2002)](https://pubmed.ncbi.nlm.nih.gov/12176023/)
[Wagner et al., Renal amino acid transport (2001)](https://pubmed.ncbi.nlm.nih.gov/11744620/)
[Forster et al., SLC17 family of vesicular glutamate transporters (2011)](https://pubmed.ncbi.nlm.nih.gov/22011206/)
[Bjork et al., SLC3A1 mutations and cystinuria (2020)](https://pubmed.ncbi.nlm.nih.gov/32952134/)
[Chillaron et al., Amino acid transport disorders and brain function (2011)](https://pubmed.ncbi.nlm.nih.gov/21878366/)
[Brahm, Urea and amino acid transport (2017)](https://pubmed.ncbi.nlm.nih.gov/28188652/)
[Ziegler et al., Enteral nutrition and amino acid transport (2002)](https://pubmed.ncbi.nlm.nih.gov/12084950/)
[Oxender et al., Mammalian amino acid transport systems (1985)](https://pubmed.ncbi.nlm.nih.gov/3906645/)See Also
- [Cystinuria](/diseases/cystinuria)
- [Amino Acid Transporters](/mechanisms/amino-acid-transport)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [System xc-](/mechanisms/system-xc)
- [Glutamate Transporters](/proteins/glutamate-transporters)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Kidney](/organs/kidney)
- [Intestine](/organs/intestine)
- [SLC Family](/proteins/slc-family)